Lauren C Daniel1,2, Richa Aggarwal2,3, Lisa A Schwartz2,4. 1. 1 Department of Psychology, Rutgers University-Camden , Camden, New Jersey. 2. 2 Division of Oncology, The Children's Hospital of Philadelphia , Philadelphia, Pennsylvania. 3. 3 Department of Psychology, Temple University , Philadelphia, Pennsylvania. 4. 4 Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania , Philadelphia, Pennsylvania.
Abstract
PURPOSE: Adolescents and young adults (AYA) with cancer are a vulnerable group facing more intense treatments, higher symptom burden, and poorer treatment outcomes relative to younger children. Sleep disruption is common during cancer treatment and sleep problems persist into adulthood for some survivors of AYA cancer. The developmental period of adolescence/emerging adulthood confers greater biological and behavioral risk for insufficient sleep relative to older or younger ages. Thus, understanding AYA sleep disturbances shortly after completing treatment can inform interventions to manage cancer-related symptoms and improve quality of life. METHODS: Sixty-one AYA (ages 12-25) within 1 year of finishing cancer treatment completed the Pittsburgh Sleep Quality Index (PSQI) and the Minneapolis-Manchester Quality of Life Instrument-Adolescent Form. Treatment variables were extracted from electronic medical records. RESULTS: Forty-seven percent of participants were classified as "poor sleepers," 41% reported prolonged sleep onset latency (>30 minutes), 31% reported sleep efficiency suggestive of insomnia, and 33% slept <8 hours nightly. Age moderated the relationship between time off treatment and PSQI total score: for younger AYA the relationship was positive and for older AYA the relationship was negative. Better sleep and higher quality of life were strongly related (r = -0.57, p < 0.001). CONCLUSIONS: For almost half of AYA cancer survivors studied, sleep is disrupted as indicated by long sleep-onset latencies, sleep efficiency suggestive of insomnia, and inadequate total sleep time. Screening for sleep disturbances after AYA complete cancer therapy may reduce the impact of sleep on quality of life and identify those at risk for insomnia.
PURPOSE: Adolescents and young adults (AYA) with cancer are a vulnerable group facing more intense treatments, higher symptom burden, and poorer treatment outcomes relative to younger children. Sleep disruption is common during cancer treatment and sleep problems persist into adulthood for some survivors of AYA cancer. The developmental period of adolescence/emerging adulthood confers greater biological and behavioral risk for insufficient sleep relative to older or younger ages. Thus, understanding AYA sleep disturbances shortly after completing treatment can inform interventions to manage cancer-related symptoms and improve quality of life. METHODS: Sixty-one AYA (ages 12-25) within 1 year of finishing cancer treatment completed the Pittsburgh Sleep Quality Index (PSQI) and the Minneapolis-Manchester Quality of Life Instrument-Adolescent Form. Treatment variables were extracted from electronic medical records. RESULTS: Forty-seven percent of participants were classified as "poor sleepers," 41% reported prolonged sleep onset latency (>30 minutes), 31% reported sleep efficiency suggestive of insomnia, and 33% slept <8 hours nightly. Age moderated the relationship between time off treatment and PSQI total score: for younger AYA the relationship was positive and for older AYA the relationship was negative. Better sleep and higher quality of life were strongly related (r = -0.57, p < 0.001). CONCLUSIONS: For almost half of AYA cancer survivors studied, sleep is disrupted as indicated by long sleep-onset latencies, sleep efficiency suggestive of insomnia, and inadequate total sleep time. Screening for sleep disturbances after AYA complete cancer therapy may reduce the impact of sleep on quality of life and identify those at risk for insomnia.
Entities:
Keywords:
cancer survivor; insomnia; quality of life; sleep
Authors: Elizabeth Donovan; Sarah R Martin; Laura C Seidman; Lonnie K Zeltzer; Tara M Cousineau; Laura A Payne; Meredith Trant; Marjorie Weiman; Marla Knoll; Noah C Federman Journal: JMIR Mhealth Uhealth Date: 2019-03-18 Impact factor: 4.773
Authors: Shosha H M Peersmann; Martha A Grootenhuis; Annemieke van Straten; Wim J E Tissing; Floor Abbink; Andrica C H de Vries; Jacqueline Loonen; Helena J H van der Pal; Gertjan J L Kaspers; Raphaële R L van Litsenburg Journal: Cancers (Basel) Date: 2022-07-07 Impact factor: 6.575
Authors: Emma Vaughan; Maria Ftanou; Jeremy Lewin; Andrew Murnane; Ilana Berger; Joshua F Wiley; Martha Hickey; Dani Bullen; Michael Jefford; Jeremy Goldin; Jeremy Stonehouse; Kate Thompson Journal: Pilot Feasibility Stud Date: 2022-07-28
Authors: Anne Sophie Lind Helligsoe; Kathrine Synne Weile; Line Kenborg; Louise Tram Henriksen; Yasmin Lassen-Ramshad; Ali Amidi; Lisa Maria Wu; Jeanette Falck Winther; Line Pickering; René Mathiasen Journal: Front Neurosci Date: 2022-02-22 Impact factor: 4.677
Authors: Lauren C Daniel; Raphaele R L van Litsenburg; Valerie E Rogers; Eric S Zhou; Sarah J Ellis; Claire E Wakefield; Robyn Stremler; Lisa Walter; Valerie McLaughlin Crabtree Journal: Psychooncology Date: 2019-11-03 Impact factor: 3.955